237690.KQ ST Pharm Co.,Ltd.
KOEHealthcareAs of 2026-08-09 03:17
Why 237690.KQ matters now
ST Pharm Co.,Ltd. (237690.KQ) is a Korea stock in Healthcare. The latest InvestLog snapshot shows ₩100,100.00 with -1.18% on the session and ₩2.09T in market capitalization.
Valuation context is available even where detailed statement rows are sparse: InvestLog currently shows P/E 27.08, gross margin 29.2%, and operating margin 18.3%.
Valuation
P/E (TTM)
27.08
PEG
—
P/B
3.40
P/S
5.40
EV/EBITDA
21.38
DCF Value
—
FCF Yield
3.1%
Div Yield
0.5%
Margins & Returns
Gross Margin
29.2%
Operating Margin
18.3%
Net Margin
19.9%
ROE
13.6%
ROA
9.0%
ROIC
8.9%
Listing Info
Market
Korea
Exchange
KOE
Currency
KRW
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Country
KR
Operating as a Contract Development and Manufacturing Organization (CDMO), ST Pharm Co. Ltd. provides pharmaceutical and non-pharmaceutical products within South Korea. Its comprehensive Chemistry, Manufacturing, and Controls (CMC) services include the development of analytical methods, in-house reference standard testing, qualification and validation of analytical techniques, detailed analytical characterization, and robust CMC documentation. The company also specializes in oligonucleotide-based products, such as antisense oligonucleotides, siRNA, miRNA, aptamers, CpG, and decoy molecules, as well as monomers and phosphoramidites. Additionally, ST Pharm manufactures generic Active Pharmaceutical Ingredients (APIs) for a broad range of therapeutic areas, including anti-cancer, anti-coagulant, anti-fungal, anti-hyperlipidemia, anti-hypertensive, anti-tuberculosis, asthma, COPD, cough suppression, diabetes mellitus, epilepsy, hepatitis B, and erectile dysfunction medications, along with ingredients for MRI contrast agents. Beyond its pharmaceutical focus, the firm supplies components for secondary batteries, electronic materials, and polymer catalysts. Founded in 1983 as Samchully Pharmaceutical Company Ltd., ST Pharm Co. Ltd. is headquartered in Seoul, South Korea.